Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices
Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapyThe products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy supportThe planned launch follows an amendment to federal regulations allowing physicians to…